← back to rankingGH · Guardant Health, Inc.
Medical - Diagnostics & Research · mkt cap $17.3B · calls: Q1 FY2026 vs Q4 FY2025
55.0 conviction · conf-adj 55
conf 3/10 partial
enthusiasm:24.0 · trend:8 · quantifies:0 · impact:0 · under_radar:0 · credibility:12 · business_impact:8 · disruption:0 · commitment:0 · confirmation:3
Enthusiasm latest 8 / prev 7 (rising)
Guardant frames AI substantively as InfinityAI/Smart Apps on oncology liquid biopsy and biopharma data—not screening—with rising rhetoric in Q1 (AACR counts, Japan ENHERTU RWE, stronger competitive positioning vs. peers). Management links AI to adoption and partner value qualitatively but never isolates AI-driven revenue, margin, or productivity in dollars or headcount. Credibility is moderate: named platform outputs (15→ongoing smart apps, 25 InfinityAI abstracts, one regulatory win) support a data-flywheel story; Helmy’s exabyte/“leading the pack” claims and Kyle’s external-AI M&A prompt remain forward-looking and unquantified on P&L.
GROUNDED NEXT-FY IMPACT vs CONSENSUS
Grounded on actual base — revenue $1.0B · net income $-0.4B · net margin -42.4% · diluted EPS -3.32
These are next-fiscal-year annual uplift estimates, not next-quarter numbers.
Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: inline · priced in: high · confidence: 3/10
| Claim | Figure | Arithmetic | Next-FY Rev % | Next-FY EPS % |
|---|
25 of 38 AACR abstracts used InfinityAI findings
other · soft | 25 of 38 | Scientific-output / platform-maturity metric (65.79% of AACR 2026 abstracts). No price, volume, or revenue line attached; not translatable to consolidated revenue or EPS (loss-making NI base). | | |
15 Infinity-AI smart applications on Guardant360 Liquid
other · soft | 15 | Product-feature count (Q4 FY25). No disclosed revenue-per-app, attach rate, or ASP uplift; Guardant360 Liquid revenue line not disclosed in inputs. No isolable revenue. | | |
Data moat: >1M samples, 500k epigenetic profiles, 100+ tumor types
other · soft | 1M samples; 500k profiles; 100+ tumor types | AI training-data scale / competitive moat (Q1 FY26). Strategic, not commercial; no monetization path, pricing, or revenue conversion quantified. No arithmetic path. | | |
Guardant360 Liquid volume +30% YoY, supported in part by Smart Apps (Q1 FY26)
engagement · soft | 30% YoY | Segment VOLUME growth rate, not consolidated revenue. Only 'supported in part' by Smart Apps — AI-attributable fraction undisclosed; Guardant360 Liquid revenue base not given in inputs. Per the soft rule (a % with no base obtainable from inputs) this cannot be converted to a consolidated rev_uplift_pct without inventing mix. Illustrative upper bound if liquid=100% of rev: 0.30*$982.021M=$294.6M (=30.0% of revenue, NOT asserted). EPS not computed (FY25 NI -$416.277M<=0). Consensus already models +33.78% total FY26 rev growth, so this is embedded in trajectory, not incremental. | | |
Guardant360 Liquid volume +nearly 30% YoY from Smart Apps (Q4 FY25)
engagement · soft | nearly 30% YoY | Prior-quarter restatement of the same liquid-volume metric; 'nearly 30%' modeled as 30%. Same limitation: segment volume rate, AI fraction not disclosed, revenue base not given. Counted once, not separately additive to claim #4. | | |
Assumptions: FY25 base: revenue $982.021M, net income -$416.277M (net margin -42.39%), diluted shares 125.374M (EPS -$3.32). All claims adopter-side (AI improves GH testing/data products; no AI-infrastructure supplier revenue). No incremental margin or tax rate applied: no hard AI-specific revenue or cost figure is isolable. The ~30% Guardant360 Liquid metric is a segment VOLUME rate, not consolidated revenue, and is a % with no obtainable revenue base in the quantified claims (DISCLOSED-BASE rule: do not invent mix) and only 'in part' AI-attributable -> soft, not convertible. EPS guardrail: company loss-making, so EPS-uplift % is meaningless and set to null. Forward qualitative statements (pipeline cadence, exabyte ambition, biopharma partnerships, more Smart Platform apps) have no $/% anchors -> excluded. Consensus comparison uses FY26/FY27 revenueAvg vs FY25 actual.
Top line: All five quantified AI claims are adopter-side. Three are non-commercial (AACR 25/38 abstract count, 15-app feature count, 1M-sample data moat) with no path to revenue. The two revenue-relevant items are the same metric across quarters: Guardant360 Liquid volume +~30% YoY, explicitly only 'supported in part' by Smart Apps. That is a segment volume rate, not consolidated revenue; with no liquid revenue $ in claims and no AI-attribution %, no clean consolidated AI increment can be computed. Consensus already embeds strong growth: FY26 revenueAvg $1,313.726M vs FY25 actual $982.021M = +33.78%, so the ~30% liquid volume lift is directionally consistent with but not above the modeled trajectory. est_rev_uplift_pct = null (no isolable above-consensus AI uplift).
Bottom line: Company is loss-making: FY25 net income -$416.277M, net margin -42.39%, GAAP EPS -$3.32. Per the loss-making guardrail an EPS-uplift % off this base is meaningless, so est_eps_uplift_pct = null. No quantified cost, productivity, or margin claim was given to size operating leverage. Consensus itself projects continued losses improving only modestly (FY26 netIncomeAvg -$379.749M, FY27 -$258.308M; EPS -$2.93/-$2.02), confirming no near-term earnings base to lift.
[impact n/m (all claims soft/unanchored); EPS uplift n/m (loss-making base)] Consensus FY26 revenue $1,313.726M is +33.78% over FY25 $982.021M (and FY27 +28.94% to $1,693.976M). The 30% Guardant360 Liquid volume growth and Smart Apps traction are presented as supporting this already-modeled growth, not as an additional layer, and only 'in part' AI-attributable — so the AI contribution sits inside the consensus revenue line. AACR 25/38 (65.79%), 15 apps, and 1M/500k data scale are credibility/moat metrics without $ bridges. On the bottom line, consensus stays in loss through FY27, so there is no positive EPS expectation for AI to beat. No quantified AI figure points clearly above the trajectory consensus assumes.
MODEL CONSENSUS (impact)
partial
Agreed on all verdicts and aggregates; conflict only on whether segment volume 30% is a hard consolidated rev uplift — resolved conservatively to null/soft.
Conflicts reconciled
- math[3].rev_uplift_pct & soft: X=null/soft=true vs Y=30/soft=false -> used null/soft=true because 30% is a segment VOLUME rate with no obtainable revenue base (a % with no base = soft per rule), and storing 30 as a consolidated rev uplift contradicts Y's own 'not computable/not asserted' note
- math[4].rev_uplift_pct & soft: X=null/soft=true vs Y=30/soft=false -> used null/soft=true, same reasoning
- math[0].type & math[1].type: X=other vs Y=engagement -> used other; abstract count and app-count are output/feature metrics, not engagement/take-rate
| Field | Opus 4.8 | GPT-5.5 |
|---|
| Rev uplift % | – | – |
| EPS uplift % | – | – |
| Priced in | high | – |
| vs analysts | inline | – |
| Confidence | 3 | – |
| Top line | All five quantified AI claims are adopter-side. Three are non-commercial (AACR abstract count, 15-app feature count, 1M-sample data moat) with no path to revenue. The two revenue-relevant items are the same metric across quarters: Guardant360 Liquid volume +~30% YoY, explicitly only 'supported in part' by Smart Apps. The AI-specific fraction is undisclosed and the liquid revenue base is not given, so no clean AI increment can be computed. Critically, consensus already models +33.8% total revenue growth ($982.0M -> $1,313.7M FY26), so the ~30% liquid volume growth is consistent with and embedded in the existing trajectory rather than above it. est_rev_uplift_pct = null (no isolable above-consensus AI uplift). | – |
| Bottom line | Company is loss-making: net income -$416.3M, net margin -42.4%, GAAP EPS -$3.32. Per the loss-making guardrail an EPS-uplift % off this base is meaningless, so est_eps_uplift_pct = null. Consensus itself projects continued losses (EPS -$2.93 FY26, -$2.02 FY27), confirming no near-term earnings base to lift. Smart Apps may eventually aid operating leverage on the Guardant360 line, but management gave no quantified cost, margin, or productivity figure to size it. | – |
| Reasoning | Consensus FY26 revenue $1,313.7M is +33.8% over FY25 $982.0M (and FY27 +28.9% on top). The 30% Guardant360 Liquid volume growth and Smart Apps traction are presented as supporting this already-modeled growth, not as an additional layer — so the AI contribution is already inside the consensus revenue line. On the bottom line, consensus stays in loss through FY27, so there is no positive EPS expectation for AI to beat. No quantified AI figure points clearly above the trajectory consensus assumes. | – |
Rows highlighted where the two models disagreed.
QUANTIFICATIONS
AACR abstracts with InfinityAI-generated findings: 25 of 38 (AACR 2026 (Q1 call period), topline)
“25 of the abstracts featured InfinityAI generated findings, which speaks to how rapidly this platform is maturing.”
Smart applications on Guardant360 Liquid (Infinity AI-developed): 15 (as of Q4 FY2025, topline)
“We have already applied Infinity AI to develop 15 smart applications on Guardant360 liquid”
Patient sample / epigenetic data scale (AI training moat): over 1 million patient samples; 500,000 epigenetic profiles; more than 100 tumor types (Q1 FY2026, topline)
“Our data repository harnesses insights from over 1 million patient samples, 500,000 epigenetic profiles across more than 100 tumor types”
Guardant360 Liquid volume growth (attributed in part to Smart Apps): 30% year-over-year (Q1 FY2026, topline)
“Guardant360 Liquid volumes grew 30%, supported by expanding clinical utility and continued traction of our Smart Apps.”
Guardant360 Liquid volume growth (Smart apps): nearly 30% year-over-year (Q4 FY2025, topline)
“Guardant360 liquid volumes increased nearly 30%, supported by expanding clinical utility from Smart apps launched over the past year”
PAST (realized)
- Q4 FY2025 | Helmy: We have already applied Infinity AI to develop 15 smart applications on Guardant360 liquid
- Q4 FY2025 | Helmy: we have seen exceptional growth in our oncology business, primarily due to the new capabilities and insights enabled by our smart apps
- Q4 FY2025 | AmirAli: We recently completed the acquisition of MetaSight Diagnostics, which brings a new technology in-house that is complementary to the Smart Platform
- Q1 FY2026 | Helmy: we are the first to bring AI pathology to the oncology space with the Lunit collaboration we did a few years ago
- Q1 FY2026 | Helmy: In the quarter, real-world evidence generated from InfinityAI as supplemental data alongside clinical findings contributed to the first tumor-agnostic approval of Daiichi Sankyo's ENHERTU in Japan
CURRENT (now)
- Q1 FY2026 | Helmy: InfinityAI powering a steady cadence of new clinical applications that are driving deeper adoption among oncologists
- Q1 FY2026 | Helmy: 25 of the abstracts featured InfinityAI generated findings
- Q1 FY2026 | Helmy: concrete evidence of InfinityAI enabling therapeutic response prediction and improving detection of clinically challenging alterations like ALK-fusions and MTAP deletions
- Q1 FY2026 | Helmy: growing strategic value of our smart platform and InfinityAI to leading biopharma companies
- Q1 FY2026 | Michael Bell: Guardant360 Liquid volumes grew 30%, supported by expanding clinical utility and continued traction of our Smart Apps
- Q4 FY2025 | Helmy: Our Smart Platform is driving a clear step change in oncology volumes
- Q4 FY2025 | Helmy: advanced drug response prediction and biomarker insights using multimodal AI
FORWARD (guidance)
- Q1 FY2026 | Helmy: we have a strong pipeline of additional smart apps in development, and we look forward to continuing that cadence
- Q1 FY2026 | Helmy: continue to scale our InfinityAI platform
- Q1 FY2026 | Helmy: over the coming quarters us really sharing a lot more in terms of all the exciting things that we're building with AI
- Q1 FY2026 | Helmy: I'll be one of the first to amass an exabyte of data
- Q4 FY2025 | Helmy: additional strategic biopharma and Infinity AI data partnerships
- Q4 FY2025 | Helmy: We expect to release additional apps driven by our Smart Platform
TRACK RECORD — PROMISE vs DELIVERY
82/100 track record delivers 6 calls reviewed
Guardant’s quantified AI/ML commitments (MCD dataset timing, Infinity AI Smart-app counts, and data-scale milestones) were mostly met on schedule with reported metrics in later calls. The notable exception is the nationwide MCD evidence-generation cohort sized at hundreds of thousands of participants, which was not updated after launch.
Present Shield MCD validation in ~800 patients across 10 cancer types at a scientific conference in Q2 2025 — promised Q4 FY2024
delivered Q1 FY2025 reported AACR presentation with quantified MCD performance (e.g., 60% overall sensitivity, 89% cancer-site-of-origin accuracy) and later calls cited the data in NCI Vanguard selection.
Present 18 AACR abstracts highlighting new Smart/Infinity AI–enabled clinical applications in 2025 — promised Q1 FY2025
delivered Management presented the Infinity AI–driven app wave at AACR and subsequently reported 11 new Smart Liquid Biopsy apps at ASCO and 15 cumulative Smart apps on Guardant360 Liquid by Q3 FY2025.
Launch ~11 new Smart Liquid Biopsy / Infinity AI clinical applications for Guardant360 Liquid (ASCO 2025 wave) — promised Q2 FY2025
delivered Q2 FY2025 stated nearly a dozen apps launched in the quarter; Q3–Q4 FY2025 reiterated 15 Smart apps live and continued cadence of new Infinity AI–powered features.
Reach 15 Smart apps on Guardant360 Liquid developed via Infinity AI — promised Q3 FY2025
delivered Q4 FY2025 and Q1 FY2026 again cited 15 Smart apps on Guardant360 Liquid and ongoing InfinityAI pipeline, with AACR 2026 noting 25/38 abstracts used InfinityAI-generated findings.
Nationwide Shield MCD clinical data initiative to reach hundreds of thousands of participants — promised Q3 FY2025
quietly-dropped Later calls described nationwide MCD opt-in rollout and building the largest U.S. MCD outcomes database but never reported progress toward the hundreds-of-thousands participant target.
Apply Infinity AI across a data treasury of 1M+ patient samples (350K+ epigenetic profiles) to power new products — promised Q3 FY2025
delivered Q1 FY2026 reported 1M+ patient samples and 500K epigenetic profiles feeding InfinityAI smart-app and biopharma RWE work.
PRICED-IN (REFINED)
HIGH (already in)Est. revisions rising · Fwd P/E -42.2 · EV/Sales 16.6x
AI claim maps to Biopharma & Data, Oncology, Screening
Analyst price targets show clear upward momentum (lastMonthAvg $147.4 vs lastQuarter $142 vs lastYear $117), and consensus already embeds ~35% revenue growth to 2026 and ~29% to 2027 while EPS losses narrow—signals the market has been revising expectations higher. At EV/Sales ~16.6x on ~$973M forward revenue with negative forward EPS (-$3.08), GH trades at a rich premium for an unprofitable diagnostics name, implying substantial future growth is already capitalized. AI-driven efficiency or revenue upside would most plausibly accrue to Biopharma & Data and core Oncology/Screening lines, but those segments are already the growth engine behind rising estimates. Rising revisions plus stretched valuation point to AI upside being largely priced in.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
3Q4 FY20247Q1 FY20257Q2 FY20258Q3 FY20257Q4 FY20258Q1 FY2026
AI enthusiasm across 6 calls — trend ↗ rising
No AI story in Q4 FY2024; Infinity AI became a core oncology and biopharma driver with apps, data scale, and regulatory proof.
RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY
7/10 qualitative impact material medium-term · mixed evidence
Where AI matters: oncology liquid biopsy Smart Apps / InfinityAI
InfinityAI is embedded in Guardant360 (15+ Smart Apps, AACR/regulatory proof) and management ties it to ~30% liquid volume growth and biopharma RWE, but there is no isolated AI revenue or margin bridge and Smart Apps only partly explain growth already in consensus.
Caveats: No P&L attribution for AI vs overall oncology growth; ~30% liquid volume lift may already be in ~34% FY26 revenue consensus; Competitors can apply similar ML if they close the data gap; Screening/MCD AI benefits less proven than core oncology
AI DISRUPTION / CANNIBALIZATION RISK tailwind · 3/10
The economic model is FDA-backed tests and proprietary oncology sample scale, not billable labor; AI mainly improves interpretation and product cadence rather than replacing the assay, though cheaper AI-native competitors could pressure pricing over time.
OPTIONS / MARKET STRUCTURE
option liquidity: good
proxy inputs — dollar-ADV $278M · beta 1.489 · px $130.17
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.
CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 6/10 measured.
INSIDERS selling 26 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 74 new / 88 closed positions; 263 increased / 161 reduced; institutional ownership +1.72pp; -18 net 13F holders
MGMT LANGUAGE 6/10 measured InfinityAI tied to volume growth and a regulatory win; mostly present/past tense ownership, limited forward AI numbers or timelines.
commit “InfinityAI powering a steady cadence of new clinical applications that are driving deeper adoption among oncologists.”
commit “Real-world evidence generated from InfinityAI as supplemental data contributed to the first tumor-agnostic approval of Daiichi Sankyo's ENHERTU in Japan.”
hedge “We have a strong pipeline of additional smart apps in development, and we look forward to continuing that cadence.”
VERBATIM AI QUOTES
“Smart platform innovation continues to translate directly into volume growth for both products with InfinityAI powering a steady cadence of new clinical applications that are driving deeper adoption among oncologists.”
— Helmy Eltoukhy, Q1 FY2026
“By applying our InfinityAI learning engine to this expanding data moat, we uncover novel biological signatures, power new smart app development and accelerate therapeutic discovery for our biopharma partners.”
— Helmy Eltoukhy, Q1 FY2026
“25 of the abstracts featured InfinityAI generated findings, which speaks to how rapidly this platform is maturing.”
— Helmy Eltoukhy, Q1 FY2026
“We were particularly encouraged to see concrete evidence of InfinityAI enabling therapeutic response prediction and improving detection of clinically challenging alterations like ALK-fusions and MTAP deletions.”
— Helmy Eltoukhy, Q1 FY2026
“In the quarter, real-world evidence generated from InfinityAI as supplemental data alongside clinical findings contributed to the first tumor-agnostic approval of Daiichi Sankyo's ENHERTU in Japan.”
— Helmy Eltoukhy, Q1 FY2026
“Together, these developments reflect the growing strategic value of our smart platform and InfinityAI to leading biopharma companies and reinforce our confidence in sustained growth in this business.”
— Helmy Eltoukhy, Q1 FY2026
“Guardant360 Liquid volumes grew 30%, supported by expanding clinical utility and continued traction of our Smart Apps.”
— Michael Bell, Q1 FY2026
“In Biopharma & Data, we're advancing CDx programs and expanding strategic partnerships, including recent additions with leading biopharma companies and continue to scale our InfinityAI platform.”
— Helmy Eltoukhy, Q1 FY2026
“I feel like we've been leading the pack, frankly, in terms of real AI that has that actionable insight.”
— Helmy Eltoukhy, Q1 FY2026
“we are the first to bring AI pathology to the oncology space with the Lunit collaboration we did a few years ago.”
— Helmy Eltoukhy, Q1 FY2026
“You're seeing what we're doing with InfinityAI.”
— Helmy Eltoukhy, Q1 FY2026
“I think we'll be one of the first to amass an exabyte of data.”
— Helmy Eltoukhy, Q1 FY2026
“And data is really the raw fuel that's required to use AI to have truly actionable insights.”
— Helmy Eltoukhy, Q1 FY2026
“we built an architecture that's purpose-built from the ground up to be really deployed and utilized and worked with AI in, I think, very fruitful way.”
— Helmy Eltoukhy, Q1 FY2026
“you're going to see, I would say, over the coming quarters us really sharing a lot more in terms of all the exciting things that we're building with AI and with the enormous treasury of data that we have inside the company.”
— Helmy Eltoukhy, Q1 FY2026
“By applying our Infinity AI learning engine to this expanding data treasury, we can accelerate therapeutic discovery and biomarker development for our biopharma partners while uncovering new biological insights that reinforce our clinical franchise.”
— Helmy Eltoukhy, Q4 FY2025
“We have already applied Infinity AI to develop 15 smart applications on Guardant360 liquid, and we believe these applications meaningfully expand the clinical utility of Guardant360 liquid while further extending our leadership in the liquid CGP market.”
— Helmy Eltoukhy, Q4 FY2025
“advanced drug response prediction and biomarker insights using multimodal AI”
— Helmy Eltoukhy, Q4 FY2025
“In oncology, we introduced groundbreaking applications for Guardant360 Liquid, upgraded Guardant360 tissue onto our smart platform and expanded Reveal to support therapy monitoring.”
— Helmy Eltoukhy, Q4 FY2025
“we have seen exceptional growth in our oncology business, primarily due to the new capabilities and insights enabled by our smart apps that are increasing both the breadth and depth of ordering of Guardant360 more than a decade after its launch.”
— Helmy Eltoukhy, Q4 FY2025
“Our Smart Platform is driving a clear step change in oncology volumes.”
— Helmy Eltoukhy, Q4 FY2025
“Guardant360 continues to benefit from a consistent rollout of new Smart Platform applications which drive deeper clinical adoption.”
— Helmy Eltoukhy, Q4 FY2025
“This partnership reflects the growing role of our Smart Platform across both liquid and tissue and drug development and the strategic value of our platform to biopharma customers.”
— Helmy Eltoukhy, Q4 FY2025
“Guardant360 liquid volumes increased nearly 30%, supported by expanding clinical utility from Smart apps launched over the past year”
— Michael Bell, Q4 FY2025
“In biopharma and data, we expect new CDx approvals as well as additional strategic biopharma and Infinity AI data partnerships.”
— Helmy Eltoukhy, Q4 FY2025
“We recently completed the acquisition of MetaSight Diagnostics, which brings a new technology in-house that is complementary to the Smart Platform and also brings on an impressive team, further strengthening our world-class R&D organization.”
— AmirAli Talasaz, Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q1 FY2026, Kyle Mikson (Canaccord)): So we have this acquisition today of an AI-based kind of diagnostics company. Is this -- I mean I know it's like one example, but are you guys thinking about ways to kind of step up your AI game and offer AI-based companion diagnostics or anything of that sort?
A: Helmy Eltoukhy: Yes. In terms of the AI question, I feel like we've been leading the pack, frankly, in terms of real AI that has that actionable insight. There's a lot of talk about AI in the space, but I think you can see physicians voting with their feet when they're using our products much more than others in the space right now. And we were one of the -- we are the first to bring AI pathology to the oncology space with the Lunit collaboration we did a few years ago. You're seeing what we're doing with InfinityAI. I think we'll be one of the first to amass an exabyte of data. And data is really the raw fuel that's required to use AI to have truly actionable insights. And so we built an architecture that's purpose-built from the ground up to be really deployed and utilized and worked with AI in, I think, very fruitful way. And yes, you're going to see, I would say, over the coming quarters us really sharing a lot more in terms of all the exciting things that we're building with AI and with the enormous treasury of data that we have inside the company.
Q (Q4 FY2025, Kyle Mikson (Canaccord)): On the MetaSight acquisition, interesting to see that. Most of the consideration is tied to future commercial performance and the regulatory approval of the technology. So first one, wondering what the path is to noncancer launch is? And then second, it seems like they use mass spec, how does that factor into your NGS heavy platform?
A: AmirAli Talasaz: Yes. So we are very actually excited about this acquisition to bring a very high-quality world experts on some specific complementary technologies to our Smart Platform. So we are very excited to go to work and see what we can do. It's a small technology talking again. So let us make more progress, and we will talk about it at the right time.